Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-718 with ketamine challenge in healthy volunteers
NCT03770780Phase 1Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Allosteric Modulators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing SAGE-718 + Ketamine with Placebo + Ketamine (2 arms). Primary endpoint: Change in Glutamate and Glutamine in Brain Regions at Day 11. Started Nov 2018; status: completed.
02
Drugs
dalzanemdor
Beyond the preview
Go deeper on NCT03770780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770780.